Literature DB >> 22829993

Primary Solitary Osseous Hodgkin's Lymphoma: A Case Report and Review of the Literature.

B Geramizadeh1, M Farzaneh, M Ramzi, O R Momenzadeh.   

Abstract

Entities:  

Keywords:  Hodgkin's Lymphoma; Primary; Scapula

Year:  2012        PMID: 22829993      PMCID: PMC3398641     

Source DB:  PubMed          Journal:  Iran Red Crescent Med J        ISSN: 2074-1804            Impact factor:   0.611


× No keyword cloud information.
Dear Editor, Herein we report a case of primary Hodgkin's lymphoma (HL) of the scapula presented with shoulder pain. A 24-year-old young and healthy man presented with left shoulder pain and swelling. There was no evidence of weight loss, sweating, fever or any systemic symptoms. Laboratory evaluation was normal except for mild leukocytosis. C-reactive protein was negative and erythrocyte sedimentation was normal. Physical examination showed mild shoulder limitation of motion secondary to pain and swelling due to ill-defined mass. No peripheral lymphadenopathy was detected despite of thorough examination of the whole body. Plain X-ray showed an osteolytic lesion in the scapula. Magnetic resonance imaging (MRI) showed diffuse abnormal signal in the scapula and the coracoid process. There were soft tissue masses on both sides of spine of scapula indicating origin from the bone. Head of humerus was unremarkable (Figure 1). With the radiologic differential diagnoses of neoplastic process, the patient underwent open surgery to obtain an excisional biopsy. Pathologic examination of the biopsy showed diffuse infiltration of polymorphic population of hematopoietic cells composed of eosinophils, plasma cells, lymphocytes, PMN leukocytes and foamy histiocytes. There were many isolated mono and binucleated large Reed-Sternberg cells which were reactive with CD15, CD30 and Pax-5, but nonreactive with LCA, EMA and ALK (Figure 2 and Figure 3a and Figure 3b).
Fig. 1

(A) CT scan of the scapula, (B) MRI of the scapula

Fig. 2

H and E section of the tumor (X250)

Fig. 3

(A) IHC shows positive CD15 in RS cells, (B) IHC shows positive CD30 in RS cells

(A) CT scan of the scapula, (B) MRI of the scapula H and E section of the tumor (X250) (A) IHC shows positive CD15 in RS cells, (B) IHC shows positive CD30 in RS cells The pathologic diagnosis of classic HL, mixed cellularity was made. Abdominal and chest CT scans were re-evaluated but there was no sign of lymphadenopathy. Whole body scan showed increased radiotracer activity in the left scapula. No other focal abnormal uptake was seen in the rest of body. Chemotherapy was started for him composed of doxorubicin (25 mg/m2), bleomycin (375 mg/m2), vincristine (6 mg/m2) and dacarbazine (375 mg/m2) given on days 1 and 15 repeated every 4 weeks. After 2 cycles of this therapy, the mass was completely disappeared and after 6 months, he was doing well and disease-free. HL is a systemic disease with most common presentation in the lymph node.[1][2][3] Ten percent of HLs originate from extra nodal regions, but primary extra nodal presentation of HL occurs in less than 0.25% of patients.[4] Bone involvement occurs in 10-20% of cases. Skeletal involvement may present in four different ways: Primary osseous HL (either solitary or multi focal), simultaneously in osseous and non-osseous sites, or recurrence of disease at osseous sites.[5] There are very few case reports of primary solitary osseous HL.[5][6][7] Most malignant lymphomas of bone are diffuse large B cell non-Hodgkin and in one study during 69 years (1927-1996) among 422 malignant lymphomas of bone, 13 cases of HL of bone were reported, but none of them has been primary solitary osseous HL.[7] To the best of our knowledge, less than 30 patients have been reported in the English literature with primary manifestation of HL in a single bone.[5][8] Mean age of the reported patients with solitary osseous HL has been about 35 years and most commonly involved bones were in the humerus, vertebra, iliac crest and femur.[5] Our case was a 24-year-old man who presented with scapular pain and swelling. Scapula as a single bone of osseous HL has also very rarely been reported.[5] The patient's general condition was very well and there was no clinical or radiologic evidence of HL involvement in other sites of the body. Treatment of the patient with ABVD was very successful and after 6 months, he was doing well and completely symptom-free. As a conclusion, HL can occur in the bone as the primary site and should be kept in mind in lytic lesions of scapula.
  8 in total

1.  Solitary skeletal lesion as the primary manifestation of Hodgkin's lymphoma: a case report.

Authors:  Manas Madan; Rachna Arora; Jasbir Singh
Journal:  Acta Cytol       Date:  2010 Sep-Oct       Impact factor: 2.319

2.  Primary spinal extranodal Hodgkin's disease at two levels.

Authors:  Ferda Cağavi; Murat Kalayci; Ishak Ozel Tekin; Gamze Numanoğlu; Zeynep Cağavi; Sanser Gül; Bektaş Açikgöz
Journal:  Clin Neurol Neurosurg       Date:  2005-01-19       Impact factor: 1.876

3.  Osseous Hodgkin disease.

Authors:  M L Ostrowski; C Y Inwards; J G Strickler; T E Witzig; D E Wenger; K K Unni
Journal:  Cancer       Date:  1999-03-01       Impact factor: 6.860

Review 4.  Primary multifocal osseous Hodgkin disease: a case report and review of the literature.

Authors:  C Gebert; J Hardes; H Ahrens; H Buerger; W Winkelmann; G Gosheger
Journal:  J Cancer Res Clin Oncol       Date:  2004-12-15       Impact factor: 4.553

Review 5.  Primary bone lymphoma.

Authors:  Sharathkumar Bhagavathi; Kai Fu
Journal:  Arch Pathol Lab Med       Date:  2009-11       Impact factor: 5.534

Review 6.  [Primary multifocal osseous Hodgkin lymphoma].

Authors:  Gaku Oshikawa; Ayako Arai; Koji Sasaki; Ryo Ichinohasama; Osamu Miura
Journal:  Rinsho Ketsueki       Date:  2009-02

7.  Isolated, primary spinal epidural Hodgkin's disease in a child.

Authors:  Mohammad Samadian; Shifteh Vahidi; Fatemeh Khormaee; Haleh Ashraf
Journal:  Pediatr Neurol       Date:  2009-06       Impact factor: 3.372

8.  Primary multifocal osseous Hodgkin's lymphoma.

Authors:  Clare R Langley; Simon J W Garrett; Jill Urand; Janice Kohler; Nick M P Clarke
Journal:  World J Surg Oncol       Date:  2008-03-17       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.